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UDP-GlcNAc Analogs as Inhibitors of O-GlcNAc Transferase 
(OGT): Spectroscopic, Computational and Biological Studies 
Mattia Ghirardello,[a] Daniela Perrone,[b] Nicola Chinaglia,[b] David Sádaba,[a] Ignacio Delso,[a] Tomas 
Tejero,[a] Elena Marchesi,[b] Marco Fogagnolo,[b] Karim Rafie,[c] Daan M. F. van Aalten[c] and Pedro 
Merino*[d] 
Abstract: A series of glycomimetics of UDP-GlcNAc in which the β-
phosphate has been replaced by either an alkyl chain or a triazolyl 
ring and the sugar moiety has been replaced by a pyrrolidine ring have 
been synthesized by using different click-chemistry procedures. Their 
affinity for human O-GlcNAc transferase (hOGT) has been evaluated 
and both spectroscopically and computationally studied. The binding 
epitopes of the best ligands have been determined in solution using 
saturation transfer difference (STD) NMR spectroscopy. 
Experimental, spectroscopic and computational results are in 
agreement, pointing out the essential role for binding of the β-
phosphate. We have found that the loss of interactions from the -
phosphate can be counterbalanced by the presence of hydrophobic 
groups at a pyrroline ring acting as a surrogate of the carbohydrate 
unit. Two of the glycomimetics prepared reach inhibition in the 
micromolar scale. 
Introduction 
Protein-glycosylation, carried out by glycosyltransferases (GTs),[1] 
is a key post-translational modification in mammals.[2] Activation 
of the carbohydrate being transferred to the protein is produced 
by binding to a nucleotide diphosphate that interacts with the 
donor active site of the enzyme.[3] In the case of protein-
glycosylation only nine nucleotide sugar donors (known as Leloir 
donors) containing uridine or guanine (with the exception of CMP-
sialic acid, substrate for sialyltransferases) are substrates for 
glycosyltransferases.[4] Numerous pathological states including 
cancer[5] and neurological disorders[6] are closely related with the 
biosynthesis of glycoproteins. Inhibiting this essential biological 
process provides an obvious therapeutic target against these 
diseases.[7] Currently, the design and synthesis of inhibitors of 
glycosyltransferases is a hot topic of great interest.[8] As illustrated 
in Figure 1, several strategies are used to inhibit protein 
glycosylation.[9] The most used approach consists of modifying 
the carbohydrate unit (1).[10] Modifications at the ribose ring (2) 
and the nucleobase (3) of the nucleotide have also been reported 
but to a lesser extent.[11]
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Figure 1. Strategies towards design of GT inhibitors. 
More recently, new chemotypes like 4 far from GT substrate-like 
compounds[12] and bisubstrate inhibitors such as 5,[13] consisting 
of two conjugated fragments interacting with both donor and 
acceptor sites of the enzyme, have emerged as a promising 
alternatives (Figure 1). Modifications at the pyrophosphate 
linkage is also possible. Indeed, it is known that pyrophosphate 
derivatives have poor membrane permeability and, consequently, 
low bioavailability. For that reason, conjugated sugar-nucleotides 
linked by neutral surrogates of the pyrophosphate unit like 6 have 
also been designed as GT inhibitors.[12b, 14] 
In this context, we have studied[15] less-polar UDP-Gal and UDP-
GalNAc analogs in which the β-phosphate has been replaced by 
an alkyl chain. As a model we chose GT GalNAc-T2, an important 
GT widely distributed in human tissues that play an important role 
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in health and disease.[16] The study showed the analogs to be 
weaker binders of the enzyme than the natural substrate UDP-
GalNAc and from the crystal structure it was inferred that the β-
phosphate was required for binding to the metal ion.  
Herein we use as the O-GlcNAc transferase (OGT) as a model 
system, an enzyme that plays a crucial role in a variety of 
biological functions within the human body[17] and does not require 
the presence of a metal.[18]  Development of new inhibitors of OGT 
has been pursued for several years.[19] However, although 
promising results have been reported recently [20] finding specific 
and cell-permeable inhibitors to be used in animal models still 
remains a challenge.[21] 
In the present study, we used a total of 14 candidates (Figure 2). 
UDP-Glc and UDP-GlcNAc analogs 7 and 8, respectively, were 
chosen by analogy with our previous study with GalNAc-T2.[15] 
Some previously reported inhibitors consisted of replacing the 
sugar moiety by a different structure since it is known that the 
sugar unit has some conformational freedom.[22] On the other 
hand, it has been recently reported that the precise conformation 
of the sugar unit could play a significant role in catalysis.[23]  To 
study the effects of sugar substitution we included compounds 9-
16 in which the sugar moiety has been replaced by a pyrrolidine 
unit bearing functional groups adequate for H-bond (as in 9, 11, 
13 and 15) and hydrophobic interactions (as in 10, 12, 14 and 16). 
Finally, analogs 17-20 containing a triazole ring in place of the β-
phosphate have also been prepared (Figure 2).  
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Figure 2. Less-polar analogs of UDP-Glc and UDP-GlcNAc. 
Replacement of both phosphate groups by a triazole had been 
reported previously but the heterocyclic ring was placed close to 
the nucleoside and no biological studies were carried out.[24] More 
recently, Vidal and co-workers reported the synthesis of neutral 
analogs containing glycosyltriazoles, in which both phosphate 
groups were replaced and suggested that the presence of the 
triazole ring results in additional interactions when a divalent 
metal ion is  required for catalysis[14a,20a]. Our approach also 
consists of employing glycosyltriazoles, however only the β-
phosphate is replaced in order to determine the exact equivalence 
between the β-phosphate and the triazole ring in enzymes that do 
not require a metal ion for catalysis. The chemical synthesis, 
biological evaluation and computational studies of the prepared 
compounds 7-20 will be discussed in the present work. 
Results and Discussion 
Synthesis of UDP-GlcNAc Analogs.  
The synthesis of compounds 7 and 8 have been reported in our 
previous study with GalNAc-T2.[15] Novel compounds 9-16 were 
synthesized from nitrones 21a-e through a highly diastereo-
selective allylation[25,26] and photoinduced free-radical hydro-
phosphonylation[27] as key steps (Scheme 1; for details see SI).  
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Scheme 1. Reagents and conditions: (i) allylmagnesium bromide, THF, -80 ºC, 
2 h. (ii) Zn, AcOH, H2O, 6 h, rt. (iii) Boc2O, pyridine, DCM, 16 h, rt. (iv) dimethyl 
phosphite, DPAP, hν, 30 min, rt. (v) PhSH, Et3N, dioxane, 4 h, rt. (vi) 2’,3’-di-O-
isopropylidene-uridine, BOP, DMF, iPr2EtN, 4 h, rt. (vii) TFA, H2O, 3 h, rt. (viii) 
H2, Pd(OH)2-C, Ac2O, pyridine, 12 h, rt. (ix) 2’,3’-di-O-acetyl-uridine, BOP, DMF, 
iPr2EtN, 4 h, rt. (x) 25% NH4OH, MeOH, 6 h , rt. 
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Selectively monodeprotected phosphonates 22a-e were coupled 
with partially protected uridine to give advanced intermediates 
23a-e. Deprotection of the phosphate moiety and acidic treatment 
afforded analogs 9, 10, 12, 14 and 16 in good chemical yields 
(see SI). The synthesis of completely deprotected analogs was 
carried out starting from hydrophosphonylated intermediates 22b-
d. Exchange of benzyl groups by acetyl groups was carried out 
through hydrogenation in the presence of acetic anhydride, 
compounds 24b-d being obtained in excellent yields after partial 
deprotection of the phosphonate function. Coupling with partially 
protected uridine afforded intermediates 25b-d. Complete 
deprotection of those intermediates yielded deprotected analogs 
11, 13, and 15 in good chemical yields (see SI). 
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Scheme 2. Reagents and conditions: (i) for β-26 and β-27: (EtO)3PꞏCuI, 1:1 
toluene/THF, 24 h, reflux; for α-28: CuSO4 (0.2 eq), sodium ascorbate (0.4 eq), 
THF, H2O, 20-25 min, reflux; for α-29: CuSO4 (0.2 eq), sodium ascorbate (0.4 
eq), tBuOH, H2O, 20 h, 50 ºC; then  DMTrCl, pyridine, 18 h, rt, then MeNH2 aq, 
35%, MeOH, 18 h, 70 ºC, then Ac2O, pyridine, 20 h, rt, then AcOH aq 80%, 
MeOH, 1 h, 50 ºC. (ii) DCI, MeCN, 45 min, rt. (iii) tBuOOH, decane, MeCN, 45 
min, rt.; then Et2NH, MeCN, 45 min, rt. (iv) NH4OH, MeCN, 18 h, rt. DCI: 4,5-
dicyanoimdazole 
The synthesis of compounds 17-20 started from azides 26-29, 
which were obtained from the corresponding carbohydrates (see 
SI). Intermediates 30-33 were obtained through a typical CuAAC 
“click” reaction[28] which has been widely employed in 
carbohydrate chemistry.[29] It was necessary to modify the 
reaction conditions slightly for each substrate. Whereas the 
classical copper(II) sulphate/sodium ascorbate system performed 
well for α-anomers, the reactions leading to β-anomers showed 
better results with the system (EtO)3PꞏCuI. In the case of 
compound α-29 additional transformation of the phtalimido group 
into the acetamido group was necessary (Scheme 2). Coupling 
between glycosyltriazoles 30-33 and the nucleotide unit 34 was 
realized using the phosphoramidite methodology.[30] The resulting 
intermediates 35-38 were further transformed into the target 
analogues 17-29. 
 
Biological Assays (Ki measurements with human OGT in vitro).  
Compound 7-20 were subjected to enzyme binding studies to the 
human O-GlcNAc transferase via fluorescence (Table 1).  
 
Table 1. Enzymatic inhibition of human O-GlcNAc transferase (hOGT). 
inhibitor Ki (μM)[a] 
7 920.758 
8 4769.0905 
9 5452.01875 
10 718.033 
11 2218.0595 
12 1140.0473 
13 1804.0110 
14 102.519 
15 1814.0132 
16 2262.410 
17 1439.5249 
18 231.94 
19 1048.0475 
20 589.163 
[a] Apparent Ki values were calculated by introducing an 100% displacement 
at a fictive concentration of 10 M.. 
 
Binding affinities were determined for all the compounds by 
displacement of a fluorescent probe[31] by compounds 7-20. The 
non-fluorescein modified probe was used as a positive control to 
show proper displacement. Most compounds showed no 
inhibition and only compounds 14 and 18 showed moderate 
binding. Due to the low binding affinity of the compounds, 100% 
displacement was mimicked by introducing an artificial 
concentration of 10 M, which allowed the fitting of a 4-parameter 
non-linear-regression curve fit and extrapolating apparent Ki 
values. Among the sugar analogs studied (7, 8, 17-20) the best 
result was found for the UDP-GlcNAc analogue 18 presenting a 
beta configuration at the anomeric center while the analogue 20 
with alpha configuration (the same as in the natural substrate) 
was a poor inhibitor. In fact, analogues 7 and 8, both with alpha 
configuration, showed rather high Ki values. Another noteworthy 
finding is the high Ki value for compound 8 for which the only 
difference with the natural substrate is the lack of β-phosphate. 
This finding clearly illustrates the key role of that phosphate unit 
in binding. 
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Pyrrolidinyl analogues showed high Ki values with the exception 
of compound 14 which showed a reasonable value of Ki = 102.5 
μM, the tightest binder for all the UDP-GlcNAc analogues 
evaluated (the most potent inhibitor reported to date is the product 
of the reaction, UDP, showing Kd = 0.5 µM[32]). Presumably, the 
presence of benzyl groups might promote hydrophobic 
interactions that stabilize the ligand. Indeed, successive 
elimination of benzyl groups in compounds 12 and 10 resulted in 
a notable increase of Ki values. In the case of compound 12 the 
opposite configurations of the stereogenic centers of the 
pyrrolidine ring with respect to 10 and 14 might also affect the 
binding negatively. The high values observed for analogues 11, 
13 and 15 suggest that H-bond interactions are not essential in 
that section of the binding pocket. Attempts to crystallise 
compound 14 in complex with hOGT revealed strong density for 
the UMP part in the binding site, however lacked the density for 
the rest of the ligand. Likely resulting from a high flexibility of the 
latter leading to a lack of electron density and therefore does not 
allow model building. Nevertheless, given the correct orientation 
of UMP it is possible to infer the orientation of the benzyl groups 
toward a hydrophobic pocket as computational calculations 
support (see below).  
 
Spectroscopic studies (STD-NMR experiments).  
Saturation transfer difference (STD) NMR spectroscopy[33] has 
demonstrated to be a great utility in evaluating ligand-protein 
binding affinities.[34] In particular, STD NMR allows the 
identification of binding epitopes,[35] which reflect the distances 
from ligand protons to protons of binding site residues. STD-NMR 
experiments were carried out with selected compounds to cover 
a range of Ki values, from the best ligand 14 (Ki =102 µM) to 12 
(Ki 1.14 mM). UMP was selected as a reference instead UDP 
since the low Kd (0.5 µM) of the latter will prevent the observation 
of any displacement by the added ligand. Moreover, since the 
studied ligands lack the β-phosphate, the use of UMP as a 
reference will provide a correct evaluation of the interactions of 
the glycomimetic moiety. To obtain the epitope mapping of the 
selected ligands, UMP, 10, 14 and 18 were incubated with hOGT 
at pH = 7.4 and the STD-NMR spectra were acquired at 25 ºC. 
Due to the low affinity, the experiments were carried out with a 
1:50 enzyme/ligand ratio which yielded STD spectra with the best 
quality. The analysis of the STD intensities allowed the mapping 
of the epitopes of UMP and compounds 10, 14 and 18 (Figure 3). 
The uridine moiety shows the same trend in STD intensities with 
100% relative STD enhancement for H-1 in all cases. The best 
results with strong interactions for all the uridine protons were 
found for the best ligand 14. On the other hand, compound 18 
only showed interactions for H-1, H-2 and H-1’. Remarkably, 
compound 14 showed better recognition of the uridine moiety than 
UMP. Indeed, when 14 was added to a solution containing the 
complex UMP-hOGT, only signals resembling a hOGT 14 
complex were observed in a higher intensity, showing that 14 
displaces UMP and binds hOGT with higher affinity. These results 
agree with the crystallographic structure of the complex UDP-
GlcNAc/hOGT,[17c] where the uridine hydrogens pointing towards 
the inner part of the protein show the highest intensities. The 
highest STD signals for the glycomimetic unit was also observed 
with 14 and correspond to the three phenyl rings suggesting the 
presence of important hydrophobic interactions (Figure 4, for the 
whole set of spectra see SI). 
 
 
Figure 3. Top: Epitope mapping of UMP and compounds 10, 14 and 18. Bottom: 
Comparison of STD intensities (%) of the protons of uridine moiety. 
In fact, elimination of two benzyl groups as in 10 resulted in a 
considerably loss of affinity also indicating that the remaining 
benzyl group at C-3 of the pyrrolidine ring was not essential in the 
binding. In the case of UDP-GalNAc analogue 18 only H-1 and H-
2 of the galactosamine unit showed a strong interaction with the 
protein. The triazole ring did not show any remarkable interaction 
indicating that it does not occupy a favorable position for binding. 
No strong interactions were observed for the alkyl chain in place 
of the β-phosphate confirming the loss of binding due to 
elimination of that phosphate unit. Nevertheless, whereas a weak 
interaction was observed for 10, limited interaction was observed 
in the case of 14. STD data confirmed that a pyrrolidine ring with 
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the appropriate configuration, as seen in 14, is an adequate 
scaffold for engaging the aromatic residues. However, other 
systems would be also suitable for the same task.  These 
experiments suggest the presence of a hydrophobic pocket on 
hOGT and the importance of establishing hydrophobic 
interactions with the surrounding area of the sugar residue binding 
site. 
 
 
Figure 4. Off-resonance and STD NMR spectra of 14 in complex with hOGT. 
Computational Studies (Docking and Molecular Dynamics).  
To shed additional light on the protein-ligand binding modes, 
computational studies with the best ligands 14 and 18 were 
carried out using the known structure of OGT in complex with 
UDP-GlcNAc (PDB ID: 4GZ5)[17c] as the template (comparative 
studies were also carried out with UDP-GlcNAc, 10 and 12; see 
SI). Published crystal structures of UDP-GlcNAc and UDP in 
complex with hOGT[17c] show interactions between the base 
moiety, and Ala896 (H-bond) and His901 (π,π-interactions). 
Previously reported docking studies using the crystal structure of 
OGT in complex with UDP-GlcNAc as a template, indicated the 
presence of four possible hydrogen-bonds between the GlcNAc 
residue and OGT, i.e: C6-OH/Thr560, C4-OH/Leu653, C3-
OH/Gly654 and C2-N-acyl group/His920).[36] The same studies 
suggested that the backbone carbonyl oxygen of Leu653 and the 
hydroxyl group of Thr560 contribute to binding of UDP-GlcNAc 
through key H-bond interactions and  that the C2-acetamido 
points to a hydrophobic pocket constituted by Met501, Leu502 
and Tyr841. Docking studies with β-1-triazolyl-GlcNAc analogues 
suggested interactions between the triazole ring and Thr921 and 
Thr924 resembling those from β-phosphate of UDP-GlNAc.[20a] All 
these computational studies were based on docking calculations 
and were when we applied such a type of calculation using the 
Schrodinger 2017 software package. Docking with 14 and 18 was 
performed by including both ligands in the UDP-GlcNAc binding 
site. In both cases, it was observed that the orientation of the 
nucleoside-α-phosphate unit resembles the orientation of the 
natural substrate and the same interactions are observed for both 
UDP-GlcNAc and other ligands (for details see SI). 
Molecular dynamics simulations allow studying the evolution of 
the complex and offers more valuable and representative 
information than static and minimum-energy docking calculations. 
In this context, MD simulations were previously used for 
elucidating the catalytic mechanism of OGT[37] further supported 
by structural data.[17c] These studies pointed out the key role of α-
phosphate and Asp554 as the catalytic bases, which was further 
confirmed as the most energetically favorable pathway.[38]  
 
 
Figure 5. Superimposition of ten structures of OGT/14 (A) and OGT/18 (B) 
complexes along the MD simulation from 50 to 100 ns; intermediate structures 
are shown grading from orange (starting geometry), yellow, green, blue 
(intermediate geometries) to magenta (final target geometry).  
On the other hand, when Asp554 was mutated out a complete 
loss of activity was not observed, resulting more plausible that -
phoshate could act as the catalytic base.[32] Recent structural 
studies carried out by one of us established that the peptide-
binding site imposes size and conformational restrictions.[39] In our 
studies, we used the generated poses in the docking studies for 
running MD simulations for 100 ns. A preliminary analysis showed 
that, after 50 ns, the situation is stabilized and basically the same 
orientation is found for the ligands (Figure 5,A). 
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For compound 14, however, different orientations were observed 
for the CH2OBn group at C-5 of the pyrrolidine ring whereas the 
other benzyloxy groups at C-3 and C-4 remain in the same 
orientation. Compound 18 showed to be always in the same 
orientation (Figure 5, B). A comparison between 14 and 18 
(Figure 6) revealed that both have the same preferred 
conformation for the mononucleotide unit (exo orientation of the 
nucleobase with respect to ribose unit with a dihedral angle 
C(C=O)-N(glycosydic)-C(anomeric)-O(ribose) around 180º). On 
the other hand, such a unit is oriented in a different way inside the 
binding pocket, although the same interactions were observed for 
this part of the molecule (see below). Notably, the glycomimetic 
unit in 8 (glycosyltriazol moiety) pointed towards the same 
direction than the less-fixed CH2OBn group at C-5 of the 
pyrrolidine ring of 14. This result agrees with the observed lower 
binding of 18 and supports the hypothesis that benzyl groups at 
C-3 and C-4 are required for binding, particularly the benzyl at C-
4 as compound 12, with only a single benzyl group at C-3 has a 
markedly lower affinity. 
 
 
Figure 6. Superimposition of the OGT/14 (green) and OGT/18 (blue) complexes 
found at 100 ns. 
A detailed inspection of interactions between OGT and 14 
revealed the same interactions observed in the crystal structure 
for the mononucleotide unit (Figure 7, A). The nucleobase has H-
bond interactions with Ala896 and Arg904, and hydrophobic 
interactions with His901. The ribose unit presents H-bond 
interactions with residues Lys898 (with O at C-2’ and C-3’) and 
Asp925 (with OH at C-3’). The phosphate group forms H-bond 
interactions with Lys842, Cys911, His920, Thr921 and Thr922. 
The three benzyl groups, responsible for the observed affinity are 
installed in hydrophobic pockets. An aromatic group at C-3 of the 
pyrrolidine ring is surrounded by Leu653, Phe694 and Thr560. 
The benzyl group at C-4 points towards a cavity formed by 
Ser553, Asp554, Thr560 and His558. The benzyloxymethyl group 
at C-5 is oriented towards the hydrophobic area formed by 
Pro497, His498, Met501, Thr633, Tyr655 and Pro656. Compound 
18 (Figure 7, B) shows the same interactions for the nucleobase 
(Ala896, Arg904 and His901) and H-bond to Asp925 for the ribose 
unit. 
On the other hand, interactions of the NHAc group of glucosamine 
moiety with His498 and His920, present in the crystal and MD 
simulations are lost in 18, which form H-bond interactions with 
Tyr841 and Lys842. In contrast with previous docking studies[14a], 
however are in agreement with STD-NMR experiments, where no 
interactions were found for the triazole ring.  
 
 
Figure 7. MD simulation for compound 14 (A) and 18 (B). Structures correspond 
to stable situations after 100 ns. 
Conclusions 
In the search of less-polar compounds to increase bioavailability 
of potential OGT inhibitors, we used click-chemistry procedures 
based on photoinduced free-radical hydrophosphonylation and 
copper catalyzed alkyne azide cycloaddition (CuAAC), to prepare 
a series of glycomimetics of UDP-GlcNAc in which the β-
phosphate group has been replaced by an alkyl chain. It has been 
reported that both the acetamido group and the β-phosphate play 
key roles in binding hOGT whereas -phosphate is crucial for 
catalysis.[32] The high Ki value found for compound 7 (OH instead 
NHAc) supports the key role of the acetamido group in the 
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binding.[17c] Indeed, it has been reported that OGT can transfer 
UDP-GalNAc but not UDP-Glc.[17c] However, the higher Ki value 
of 8, which has the NHAc group suggests that it is the absence of 
the β-phosphate the responsible of a wrong orientation of the 
carbohydrate unit. The -phosphate provides key hydrogen 
bonds (with Lys842 and three contiguous residues His920, 
Thr921, Thr922) that are observed in both the studied OGT-UDP-
GlcNAc complex (PDB: 4GZ5) and the ternary complex OGT-
UDP-GlcNAc-peptide (PDB: 4GYW).[17c] Both experimental and 
computational results confirm the crucial role of β-phosphate in 
binding for hOGT in a similar way to other glycosyltransferases 
requiring the presence of a metal ion, like GalNAc-T2.[15] 
Consequently, the elimination of the β-phosphate requires groups 
in the analogues capable of providing interactions to 
counterbalance those lost. In this respect, glycomimetics with free 
hydroxyl groups do not demonstrate to be good candidates 
suggesting that H-bond interactions are not the key in this case. 
On the other hand, the triazole ring give some interactions in the 
case of compound 18 (Ki = 231.9 M) in agreement with that 
reported by Vidal and co-workers.[14a] However, the best result 
was found for compound 14 (Ki = 102.5 M) with a value in the 
order to those reported in the literature.[14b] This result supported 
by STD NMR experiments and computational (docking and MD) 
calculations, points out the importance of hydrophobic 
interactions in the area of the active site occupied by the 
carbohydrate for the design of an inhibitor. 
Our study is consistent with the lower affinity of compounds in 
which the β-phosphate unit has been replaced by a different 
moiety and reaffirm the importance of the interactions of such a 
unit even in the absence of a metal for achieving a good binding, 
as in the present case of hOGT for which it has been suggested 
that Lys842 adopts the role of the metal ion. At the same time the 
study shows the possibility of introducing hydrophobic groups at 
the carbohydrate surrogate to increase affinity. In other words, the 
lower affinity caused by the absence of -phosphate is 
counterbalanced by the hydrophobic interactions of the poly-O-
benzylated pyrrolidine acting as a surrogate of the carbohydrate 
unit. A combination of this approach with the replacement of the 
β-phosphate by a functional group which provide interactions 
capable of competing with those observed in the natural substrate 
might be the way to find inhibitors of hOGT at a nanomolar level.  
Experimental Section 
Data of Final Compounds 9-20 are given. For the complete 
experimental section see SI 
Compound 9. Pale yellow oil. [α]D29 ≅ - 6 (c 1.3, H2O).  1H NMR 
(400 MHz, D2O25°C) δ 7.94 (d, 1H, J = 8.1 Hz, H-6u); 5.95 (d, 1H, 
J = 4.8 Hz, H-1’); 5.93 (d, 1H, J = 8.1 Hz, H-5u); 4.37-4.33 (m, 2H, 
H-2’, H-4); 4.31 (t, 1H, J = 5.0 Hz, H-3’); 4.28-4.24 (m, 1H, H-4’); 
4.15 (ddd, 1H, J = 11.8, 4.5, 2.5 Hz, H-5’); 4.09-4.04 (m, 1H, H-
5’); 4.05 (dd, 1H, J = 8.6, 4.2 Hz, H-3); 3.52 (dd, 1H, J = 13.0, 4.4 
Hz, H-5); 3.53-3.46 (m, 1H, H-3); 3.32 (dd, 1H, J = 13.0, 2.1 Hz, 
H-5); 1.99-1.62 (m, 6H, 2 H-6, 2 H-7, 2 H-8). 13C NMR (100 MHz, 
D2O25°C) δ 166.2 (C); 151.7 (C); 141.6 (CH-6u); 102.3 (CH-5u); 
88.9 (CH-1’); 83.1 (d, J = 7.7 Hz, CH-4’); 74.9 (CH-3); 73.8 (CH-
2’); 69.5 (CH-3’); 29.2 (CH-4); 62.8 (d, J = 5.2 Hz, CH2-5’); 60.2 
(CH-2); 49.0 (CH2-5); 30.8 (d, J = 16.4 Hz, CH2); 25.4 (d, J = 134.9 
Hz, CH2); 20.1 (d, J = 4.4 Hz, CH2). 31P NMR (162 MHz, D2O25°C) 
δ 27.5. Anal Calcd for C16H26N3O10P: C, 42.58; H, 5.81; N, 9.31; 
P, 6.86. Found: C, 44.05; H, 5.84; N, 9.54; P, 6.69. 
Compound 10. White solid. Mp: 162 °C, with decomposition. 
[α]D30 ≅ + 19 (c 1.4, H2O). 1H NMR (400 MHz, D2O25°C) δ 7.78 (d, 
1H, J = 8.0 Hz, H-6u); 7.36-7.23 (m, 5H, Ph); 5.87-5.68 (m, 1H, H-
5u); 5.79 (s, 1H, H-1’); 4.53-4.39 (m, 2H, CH2Ph); 4.20-4.10 (m, 
3H, H-2’, H-3’, H-4’); 4.07-3.99 (m, 2H, H-3, H-5’); 3.98-3.91 (m, 
1H, H-5’); 3.60-3.52 (m, 1H, H-2); 3.39-3.24 (m, 2H, 2 H-5); 2.20-
2.03 (m, 2H, 2 H-4); 1.72-1.47 (m, 6H, 2H-6, 2 H-7, 2 H-8); 13C 
NMR (100 MHz, D2O25°C) δ 165.9 (C); 151.5 (C); 141.5 (CH-6u); 
136.7 (C); 128.8 (2 CHPh); 128.4 (CHPh); 128.3 (2 CHPh); 102.3 
(CH-5u ); 89.1 (CH-1’); 83.0 (d, J = 7.7 Hz, CH-4’); 81.1 (CH-3); 
73.8 (CH-2’); 71.2 (CH2Ph); 69.3 (CH-3’); 64.1 (CH-2); 62.6 (d, J 
= 5.2 Hz, CH2-5’); 43.6 (CH2-5); 30.9 (d, J = 16.5 Hz, CH2); 29.2 
(CH2-4); 25.4 (d, J = 135.1 Hz, CH2); 20.1 (d, J = 4.3 Hz, CH2). 
31P NMR (162 MHz, D2O25°C) δ 27.3. Anal Calcd for C23H32N3O9P: 
C, 52.57; H, 6.14; N, 8.00; P, 5.89. Found: C, 51.21; H, 6.25; N, 
7.81; P,5.70. 
Compound 11. White solid. mp: 171-172 °C. [α]D28 ≅ + 16 (c 1.1, 
H2O). 1H NMR (400 MHz, D2O25°C) δ 7.89 (d, 1H, J = 8.1 Hz, H-
6u); 5.90 (d, 1H, J = 5.0 Hz, H-1’); 5.88 (d, 1H, J = 8.1 Hz, H-5u); 
4.31 (t, 1H, J = 5.0 Hz, H-2’); 4.28-4.23 (m, 2H, H-3, H-3’); 4.23-
4.18 (m, 1H, H-4’); 4.10 (ddd, 1H, J = 11.8, 4.1, 2.4 Hz, H-5’); 4.02 
(ddd, 1H, J = 11.8, 5.5, 3.2 Hz, H-5’); 3.48-3.33 (m, 3H, H-2, 2 H-
5); 2.21 (ddd, 1H, J = 14.0, 9.9, 5.7 Hz, H-4); 1.96 (ddd, 1H,  J = 
14.0, 10.3, 6.5 Hz, H-4); 1.83-1.54 (m, 6H, 2 H-6, 2 H-7, 2H-8). 
13C NMR (75 MHz, D2O25°C) δ 166.2 (C); 151.7 (C); 141.6 (CH-
6u); 102.4 (CH-5u); 88.9 (CH-1’); 83.1 (d, J = 7.7 Hz, CH-4’); 73.8 
(CH-2’); 73.6 (CH-3); 69.5 (CH-3’); 65.9 (CH-2); 62.8 (d, J = 5.3 
Hz, CH2-5’); 43.1 (CH2-5); 31.2 (CH2-4); 30.7 (d, J = 16.4 Hz, 
CH2); 25.4 (d, J = 135.1 Hz, CH2); 20.0 (d, J = 4.2 Hz, CH2). 31P 
NMR (162 MHz, D2O25°C) δ 27.4. Anal Calcd for C16H26N3O9P: C, 
44.14; H, 6.02; N, 9.65; P, 7.11. Found: C, 42.44; H, 5.84; N, 9.37; 
P, 6.94. 
Compound 12. White solid. mp: 134-135 °C. [α]D26 ≅ - 8 (c 1.0, 
MeOH). 1H NMR (400 MHz, Methanol-d4) δ 8.00 (d, 1H, J = 8.1 
Hz, H-6u); 7.39-7.28 (m, 10H, Ph); 5.95 (d, 1H, J = 4.3 Hz, H-1’); 
5.78 (d, 1H, J = 8.1 Hz, H-5u); 4.65-4.57 (m, 4H, 4 CH2Ph); 4.24-
4.18 (m, 3H, H-2’, H-3’, H-4); 4.14-4.04 (m, 3H, H-4’, 2 H-5’); 4.00 
(dt, 1H, J = 2.6, 1.2 Hz, H-3); 3.57-3.51 (m, 2H, H-2, H-5); 3.41 
(dd, 1H, J = 12.5, 4.0 Hz, H-5); 1.93-1.84 (m, 2H, 2 H-6); 1.74-
1.55 (m, 4H, 2H-7, 2 H-8). 13C NMR (75 MHz, Methanol-d4) δ 
166.1 (C); 152.5 (C); 142.6 (CH-6u); 138.7 (C); 138.6 (C); 129.6 
(2 CHPh); 129.6 (2 CHPh); 129.2 (2 CHPh);  129.2 (CHPh);  129.2 (3 
CHPh); 103.0 (CH-5u); 90.3 (CH-1’); 85.8 (CH-3); 85.0 (d, J = 7.3 
Hz, CH-4’); 81.0 (CH-2’); 75.6 (CH-3’); 73.1 (CH2Ph); 72.5 
(CH2Ph); 71.3 (CH-4); 66.5 (CH-2); 64.3 (d, J = 5.4 Hz, CH2-5’); 
50.5 (CH2-5); 33.3 (d, J = 13.8 Hz, CH2); 27.0 (d, J = 135.6 Hz, 
CH2); 22.1 (d, J = 4.4 Hz, CH2). 31P NMR (162 MHz, Methanol-d4) 
δ 25.1. Anal Calcd for C30H38N3O10P: C, 57.05; H, 6.06; N, 6.65; 
P, 4.90. Found: C, 58.31; H, 5.97; N, 6.47; P, 5.02. 
Compound 13. White solid. mp: 179-180 °C. [α]D28 ≅ - 10 (c 1.0, 
H2O). 1H NMR (300 MHz, D2O25°C) δ 7.96 (d, 1H, J = 8.1 Hz, H-
6u); 5.97 (d, 1H  J = 4.5 Hz, H-1’); 5.95 (d, 1H, J = 8.1 Hz, H-5u); 
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4.40-4.30 (m, 3H, H-2’, H-3’, H-4); 4.30-4.25 (m, 1H, H-4’); 4.21-
4.04 (m, 3H, H-3, 2 H-5’); 3.55 (dd, 1H, J = 12.6, 4.2 Hz, H-5); 
3.52-3.43 (m, 1H, H-2); 3.37 (dd, 1H, J = 12.6, 2.1 Hz, H-5); 2.07-
1.84 (m, 2H, 2 H-6); 1.81-1.60 (m, 4H, 2 H-7, 2 H-8). 13C NMR (75 
MHz, D2O25°C) δ 166.2 (C); 151.7 (C); 141.6 (CH-6u); 102.4 (CH-
5u); 88.9 (CH-1’); 83.1 (d, J = 7.7 Hz, CH-4’); 78.7 (CH-3); 74.5 
(CH-4); 73.8 (CH-2’); 69.5 (CH-3’); 65.4 (CH-2); 62.8 (d, J = 5.2 
Hz, CH2-5’); 49.9 (CH2-5); 31.7 (d, J = 16.5 Hz, CH2); 25.3 (d, J = 
135.0 Hz, CH2); 20.2 (d, J = 4.2 Hz, CH2). 31P NMR (162 MHz, 
D2O25°C) δ 27.3. Anal Calcd for C16H26N3O10P: C, 42.58; H, 5.81; 
N, 9.31; P, 6.86. Found: C, 43.45; H, 5.77; N, 9.03; P, 7.06. 
Compound 14. White solid. mp: 119-121 °C. [α]D22 ≅ + 13 (c 0.5, 
MeOH). 1H NMR (400 MHz, Methanol-d4) δ 7.99 (d, 1H, J = 8.1 
Hz, H-6u); 7.35-7.23 (m, 15H, Ph); 5.94 (d, 1H, J = 4.5 Hz, H-1’); 
5.77 (d, 1H, J = 8.1 Hz, H-5u); 4.56-4.47 (m, 6H, 6 CH2Ph); 4.22-
4.16 (m, 2H, H-2’, H-3’); 4.11-4.02 (m, 3H, H-4’, 2 H-5’); 3.99-3.97 
(m, 1H, H-4); 3.87 (dd, 1H, J = 4.2, 2.4 Hz, H-3); 3.66-3.55 (m, 
3H, H-5, 2 H-9); 3.42-3.34 (m, 1H, H-2); 1.83-1.54 (m, 6H, 2 H-6, 
2 H-7, 2 H-8). 13C NMR (75 MHz, Methanol-d4) δ 166.1 (C); 152.5 
(C); 142.5 (CH-6u); 139.1 (C); 139.1 (C); 139.0 (C); 129.5 (2 
CHPh); 129.5 (2 CHPh); 129.5 (2 CHPh); 129.3 (2 CHPh); 129.1 (2 
CHPh); 129.1 (2 CHPh); 129.0 (CHPh); 128.9 (2 CHPh); 103.0 (CH-
5u); 90.1 (CH-1’); 88.2 (CH-3); 85.0 (d, J = 7.4 Hz, CH-4’); 84.8 
(CH-4); 75.7 (CH-2’); 74.3 (CH2Ph); 73.0 (CH2Ph); 72.9 (CH2Ph); 
71.3 (CH-3’); 69.4 (CH2-9); 64.2 (d, J = 5.3 Hz, CH2-5’); 64.0 (CH-
2); 63.7 (CH-5); 34.1 (d, J = 14.7 Hz, CH2); 27.4 (d, J = 135.6 Hz, 
CH2); 22.0 (d, J = 4.2 Hz, CH2). 31P NMR (162 MHz, Methanol-d4) 
δ 25.5. Anal Calcd for C38H46N3O11P: C, 60.71; H, 6.17; N, 5.59; 
P, 4.12. Found: C, 59.76; H, 6.06; N, 5.41; P, 4.23. 
Compound 15. White solid. mp: 175-179 °C. [α]D31 ≅ + 26 (c 0.9, 
H2O). 1H NMR (400 MHz, D2O25°C) δ 7.90 (d, 1H, J = 8.1 Hz, H-
6u); 5.91 (d, 1H, J = 5.0 Hz, H-1’); 5.90 (d, 1H, J = 8.1 Hz, H-5u); 
4.32 (t, 1H, J = 5.0 Hz, H-2’); 4.28 (t, 1H, J = 5.0 Hz, H-3’); 4.24-
4.20 (m, 1H, H-4’); 4.11 (ddd, 1H, J = 11.9, 4.5, 2.5 Hz, H-5’); 4.03 
(ddd, 1H, J = 11.9, 5.4, 3.2 Hz, H-5’); 4.01 (t, 1H, J = 7.3 Hz, H-
4); 3.93 (dd, 1H, J = 8.0, 7.3 Hz, H-3); 3.89 (dd, 1H,  J = 12.7, 3.8 
Hz, H-9); 3.82 (dd, 1H, J = 12.7, 6.1 Hz, H-9); 3.51 (ddd, J = 7.3, 
6.1, 3.8 Hz, H-5); 3.38 (dt, J = 8.0, 5.6 Hz, H-2); 2.01-1.90 (m, 1H, 
H-6); 1.89-1.78 (m, 1H, H-6); 1.74-1.58 (m, 4H, 2 H-7, 2H-8). 13C 
NMR (75 MHz, D2O25°C) δ 166.1 (C); 151.7 (C); 141.6 (CH-6u); 
102.4 (CH-5u); 88.9 (CH-1’); 83.1 (d, J = 8.0 Hz, CH-4’); 78.2 (CH-
3); 74.3 (CH-4); 73.8 (CH-2’); 69.5 (CH-3’); 62.8 (d, J = 5.9 Hz, 
CH2-5’); 62.2 (CH-5); 61.0 (CH-2); 58.1 (CH2-9); 31.3 (d, J = 16.8 
Hz, CH2); 25.4 (d, J = 135.0 Hz, CH2); 19.7 (d, J = 4.8 Hz, CH2). 
31P NMR (121 MHz, D2O25°C) δ 27.5. Anal Calcd for C17H28N3O11P: 
C, 42.42; H, 5.86; N, 8.73; P, 6.43. Found: C, 41.77; H, 5.81; N, 
8.83; P, 6.26. 
Compound 16. White solid. mp: 233-236 °C. [α]D25 ≅ + 17 (c 0.4, 
H2O). 1H NMR (500 MHz, D2O25°C) δ  8.01 (d, 1H, J = 8.2 Hz, H-
6u); 7.33-7.38 (m, 2H, Ar); 7.01-7.07 (m, 2H, Ar); 6.01 (d, 1H, J = 
4.3 Hz, H-1’); 5.99 (d, 1H, J = 8.2 Hz, H-5u); 4.41 (dd, 1H, J = 4.9, 
4.4 Hz, H-2’);  4.38 (dd,1H,  J = 5.5, 4.7 Hz, H-3’); 4.31-4.35 (m, 
1H, H-4’); 4.20-4.26 (m, 1H, H-5’); 4.15 (ddd, 1H, J = 8.5, 4.7, 3.1 
Hz, H-5’);  3.87 (s, 3H, CH3O); 3.71 (dd, 1H,  J = 11.1, 7.8 Hz, H-
5); 3.46 (ddd, 1H, J = 10.2, 10.1, 4.2 Hz, H-2); 3.19-3.33 (m, 2H, 
H-4, H-5); 1.67-2.18 (m, 7H, H-3, 2 H-6, 2 H-7, 2 H-8); 1.38-1.47 
(m, 2H, CH3CH2CH2); 1.07-1.17 (m, 2H, CH3CH2CH2); 0.73 (t, J = 
7.3 Hz, 3H, CH3CH2CH2). 13C NMR (125 MHz, D2O25°C) δ 166.1 
(C); 158.2 (C); 151.7 (C); 141.7 (CH-6u); 131.2 (C);  129.1 (2 
CHAr); 114.5 (2 CHAr); 102.5 (CH-5u);  89.1 (CH-1’);  83.2 (d, J = 
7.8 Hz, CH-4’);  73.9 (CH-2’); 69.5 (CH-3’);  64.5 (CH-2);  62.9 (d, 
J = 5.3 Hz, CH2-5’);  55.5 (CH3O);  50.5 (CH2-5);  49.7 (CH-4);  
48.5 (CH-3);  32.3 (d, J = 15.6 Hz, CH2); 32.0 (CH3CH2CH2); 25.7 
(d, J = 135.1 Hz, CH2); 20.4 (d, J = 4.2 Hz, CH2); 19.3 
(CH3CH2CH2); 13.6 (CH3CH2CH2). 31P NMR (202 MHz, D2O25°C) 
δ 27.4. Anal Calcd for C26H38N3O9P: C, 55.02; H, 6.75; N, 7.40; P, 
5.46. Found: C, 57.11; H, 6.56; N, 7.42; P, 5.56. 
Compound 17. Sticky oil. [α]D25 ≅ -2 (c 1.2, H2O). 1H NMR (400 
MHz; DMSO d6): δ= 8.23 (s, 1H, C=CH-N); 7.89 (d, 1H, J=8.01 
Hz, H-6); 7.31 (s, 3H, 3OH); 6.69 (s, 3H, 3OH); 5.79 (d, 1H, 
J=5.66 Hz, H-1’); 5.62 (d, 1H, J=8.01Hz, H-5); 5.50 (d, 1H, J=9.37 
Hz, H-1g); 4.76 (d, 2H, J=6.05 Hz, CH2OP); 4.07 (t, 1H, 5.27 Hz, 
H-2’); 4.01 (t, 1H, J=3.51 Hz, H-3’); 3.94 (t, 1H, J=2.15 Hz, H-4’); 
3.90-3.80 (m, 2H, H-5’); 3.75 (t, 1H, J=9.18 Hz, H-2g); 3.65 (d, 
2H, J=10.15 Hz, H-6g); 3.46-3.37 (m, 2H, H-3g, H-5g);  3.25-3.18 
(m, 1H, H-4g); 13C-NMR (101 MHz; DMSO d6): δ= 163.27 (C=O); 
150.93 (C=O); 144.81 (CH-5u); 140.96 (=C-N); 123.05 (=CH-N); 
102.03 (CH-6u); 87.50 (CH-1’, CH-4’); 83.62 (CH-1g); 79.99 (CH); 
77.04 (CH); 73.33 (CH); 72.10 (CH); 70.44 (CH); 69.60 (CH); 
64.39 (CH2); 60.80 (CH2); 58.00 (CH2). 31P-NMR (122 MHz; 
DMSO d6): δ=-1.79. HRMS Calcd for [C18H26N5O14P+H]+ 
568.1286, Found 568.1288 
Compound 18. Sticky oil. [α]D25 ≅ +42 (c 1.6, H2O). 1H NMR 400 
MHz; DMSO-d6): =8.15 (s, 1H, C=CH-N); 7.89 (d, 1H, J=8.1 Hz, 
H-6); 7.30 (br s, 4H, NH4+); 6.12 (d, 1H, J=5.9 Hz, H-1g); 5.79 (d, 
1H, J=5.7 Hz, H-1’); 5.61 (d, 1H, J=8.1 Hz, H-5); 5.57 (d, 1H, 
J=4.9 Hz, OH); 5.49 (d, 1H, J=5.5 Hz, OH); 5.48-5.43 (m, 1H, OH); 
5.21 (d, 1H, J=4.8 Hz, OH); 5.18 (d, 1H, J=5.9 Hz, OH); 4.81-4.72 
(m, 2H, CH2OP); 4.56 (t, 1H, J=5.8 Hz, OH); 4.10-4.05 (m, 1H, H-
2’); 4.05-4.00 (m, 2H, H-3’, H-3g); 3.96-3.92 (m, 1H, H-4’); 3.89-
3.78 (m, 2H, H-5A’ e H-5B’); 3.76-3.69 (m, 1H, H-2g); 3.62 (ddd, 
1H, J=9.9, 5.3, 2.0 Hz, H-5g); 3.58-3.52 (m, 1H, H-6Ag); 3.47-3.41 
(m, 1H, H-6Bg); 3.28-3.21 (m, 1H, H-4g). 13C-NMR (101 MHz; 
DMSO-d6): =163,3 (C=O); 151,0 (C=O); 143,9 (=C-N); 141,0 
(CH-5u); 126,0 (=CH-N); 102.0 (CH-6u); 87.5 (CH-1’); 85.2 (CH-
4’); 83.7 (CH-1g); 76.5 (CH); 73.4 (CH); 72.9 (CH); 70.6 (CH); 
70.4 (CH); 69.9 (CH); 64.4 (CH2); 60.8 (CH2); 58.0 (CH2). 31P-
NMR (122 MHz; DMSO-d6): =-1.68. HRMS Calcd for 
[C18H26N5O14P+ H]+ 568.1286, Found 568.1289. 
Compound 19.  Sticky oil. [α]D25 ≅ -6 (c 2.7, H2O). 1H NMR (400 
MHz; DMSO-d6): =8.08 (s, 1H, C=CH-N); 7.98 (d, 1H, J=9.1 Hz, 
NHAc); 7.90 (d, 1H, J=8.1 Hz, H-6); 7.30 (br s, 4H, NH4+); 5.79 (d, 
1H, J=5.8 Hz, H-1g); 5.70 (d, 1H, J=9.9 Hz, H-1’); 5.60 (d, 1H, 
J=8.1 Hz, H-5); 5.53-5.30 (m, 4H, 4 OH); 4.82-4.71 (m, 1H, OH); 
4.76-4.66 (m, 2H, CH2OP); 4.09-3.99 (m, 3H, H-2’, H-3’, H-2g); 
3.95-3.91 (m, 1H, H-4’); 3.87-3.76 (m, 2H, H-5A’ e H-5B’); 3.67 (d, 
1H, J=10.8 Hz, H-6Ag); 3.55 (t, 1H, J=9,2 Hz, H-3g); 3.50-3.36 (m, 
2H, H-5g e H-6Bg); 3.27 (t, 1H, J=9.1 Hz, H-4g); 1.62 (s, 3H, Ac). 
13C-NMR (101 MHz; DMSO-d6): =169.5 (C); 163.2 (C=O); 150.9 
(C=O); 145.0 (CH-5u); 141.0 (=C-N); 122.3 (=CH-N); 102.0 (CH-
6u); 87.5 (CH); 86.0 (CH); 83.6 (CH); 80.1 (CH); 74.0 (CH); 73.4 
(CH); 70.5 (CH); 70.0 (CH); 64.4 (CH2); 60.8 (CH2); 58.0 (CH2); 
54.6 (CH-2g); 22.8 (CH3). 31P-NMR (122 MHz; DMSO-d6): =-
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1.32. HRMS Calcd for [C20H29N6O14P+ H]+ 609.1552, Found 
609.1556 
Compound 20. Sticky oil. [α]D25 ≅ +70 (c 2.4, H2O). 1H NMR (400 
MHz; DMSO-d6): =8.16 (s, 1H, C=CH-N); 7.90 (d, 1H, J=8.1 Hz, 
H-6); 7.82 (d, 1H, J=6.9 Hz, NHAc); 7.30 (bs, 4H, NH4+); 6.22 (d, 
1H, J=5,8 Hz, H-1g); 5.78 (d, 1H, J=5.7 Hz, H-1’); 5.58 (d, 1H, 
J=8.1 Hz, H-5); 4.80-4.71 (m, 2H, CH2OP); 4.25 (dd, 1H, J=10.8, 
8.5 Hz, H-3g); 4.10-4.03 (m, 2H, H-2’, H-2g); 4.03-3.98 (m, 1H, H-
3’); 3.95-3.90 (m, 1H, H-4’); 3.88-3.76 (m, 2H, H-5A’ e H-5B’); 3.53 
(dd, 1H, H=14, 4.7 Hz, H-6Ag); 3.47-3.40 (m, 2H, H-5g e H-6Bg); 
3.32 (t, 1H, J=8.9 Hz, H-4g); 1.67 (s, 3H, Ac). 13C-NMR (101 MHz; 
DMSO-d6): =170.4 (Ac); 163.2 (C=O); 150.9 (C=O); 144.4 (=C-
N); 141.0 (CH-5u); 125.8 (=CH-N); 102.0 (CH-6u); 87.5(CH-1’); 
83.6 (CH-4’); 83.0 (CH-1g); 76.2 (CH); 73.4 (CH); 73.0 (CH); 70.5 
(CH); 70.2 (CH); 64.4 (CH2); 60.6 (CH2); 57.9 (CH2); 53.4 (CH-
2g); 22.3 (CH3). 31P-NMR (122 MHz; DMSO-d6): =-1.35. HRMS 
Calcd for [C20H29N6O14P+ H]+ 609.1552, found 609.1556 
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